Lipoproteins and low-dose estradiol replacement therapy in post-menopausal Type 2 diabetic patients: the effect of addition of norethisterone acetate

التفاصيل البيبلوغرافية
العنوان: Lipoproteins and low-dose estradiol replacement therapy in post-menopausal Type 2 diabetic patients: the effect of addition of norethisterone acetate
المؤلفون: Daphne Owens, G. H. Tomkin, Alan H. Johnson, Patrick Collins
المصدر: Diabetic Medicine. 17:308-315
بيانات النشر: Wiley, 2000.
سنة النشر: 2000
مصطلحات موضوعية: medicine.medical_specialty, Very low-density lipoprotein, Lipoproteins, Endocrinology, Diabetes and Metabolism, Blood lipids, Lipoproteins, VLDL, chemistry.chemical_compound, Endocrinology, High-density lipoprotein, Double-Blind Method, Internal medicine, Cholesterylester transfer protein, Internal Medicine, medicine, Humans, Triglycerides, Aged, Glycoproteins, Estradiol, biology, Cholesterol, business.industry, Estrogen Replacement Therapy, Middle Aged, Norethisterone acetate, Cholesterol Ester Transfer Proteins, Lipoproteins, LDL, Postmenopause, Norethindrone Acetate, Diabetes Mellitus, Type 2, chemistry, Low-density lipoprotein, biology.protein, Drug Therapy, Combination, Female, lipids (amino acids, peptides, and proteins), Norethindrone, Carrier Proteins, Lipoproteins, HDL, business, Lipoprotein, medicine.drug
الوصف: Aims Low-dose continuous oestrogen/progestogen may increase patient compliance long-term but the cardioprotective effects in diabetes are unknown. The aim of this study was to compare the effect of low-dose oral oestrogen (1 mg, 17-β-estradiol) treatment with oestrogen (1 mg 17-β-estradiol) in combination with low-dose (0.5 mg) continuous norethisterone acetate (NETA) on lipoproteins in Type 2 diabetic patients. Methods Thirty-four post-menopausal Type 2 diabetic patients in moderate control (mean haemoglobin A 1c 7.7%) who had a serum oestradiol level of < 50 pg/ml were examined over a 6-month period. Serum lipids, and lipoprotein composition of very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) were measured. Serum lipoprotein(a) was determined by an ELISA method, LDL fatty acids by gas-liquid chromatography and LDL oxidizability by thiobarbituric acid reactive substances (TBARS assay). Cholesteryl ester transfer protein (CETP), and cell cholesterol were measured. Results There was a reduction in serum cholesterol on both treatments but no significant difference between treatment groups. LDL cholesterol decreased by 17% in each group. There was a no significant difference between the groups in serum VLDL or HDL cholesterol or serum triglycerides during the study. The change in lipoprotein(a) during the study was not significantly different between the groups. There was no significant difference in 4 h LDL oxidizability between groups. Although CETP increased with time in both groups there was no significant difference in the change between the groups. Conclusion In this small study, the addition of continuous low-dose NETA did not reduce the potentially beneficial effects of low-dose 17-β-estradiol on the progression of atherosclerosis in diabetes. Diabet. Med. 17, 308-315 (2000) Keywords 17-β-estradiol, cell cholesterol, cholesteryl ester transfer protein, hormone replacement therapy, LDL fatty acids, lipoprotein composition, norethisterone acetate, plasma cholesterol, Type 2 diabetes mellitus Abbreviations CETP, cholesteryl ester transfer protein; FSH, follicle stimulating hormone; HDL, high density lipoprotein; HRT, hormone replacement therapy; LDL, low density lipoprotein; Lp(a), lipoprotein(a); NETA, norethisterone acetate; TBARS, thiobarbituric acid reactive substances; VLDL, very low density lipoprotein
تدمد: 1464-5491
0742-3071
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5dccf09acc2d762c04ff48317e01ccb
https://doi.org/10.1046/j.1464-5491.2000.00281.x
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....d5dccf09acc2d762c04ff48317e01ccb
قاعدة البيانات: OpenAIRE